Chapter 18 — Further Reading

TB-500, Thymosin Alpha-1, and Other Recovery and Immune Peptides

This chapter's sources are sorted into three tiers by how much you should trust the specifics of an entry as written here. That sorting is itself the lesson: this is a field where a great deal of confident writing rests on sources nobody checked, and a reading list that pretends to uniform reliability would be modeling the exact failure the chapter describes.

Tier 1 — Verified canonical

Sources whose existence, identity, and general content are not in doubt. These are standing references rather than individual papers, which is deliberate: standing references can be located and checked by anyone, and they do not decay the way a specific citation does.

Trial registries. Public, searchable registries of clinical trials — ClinicalTrials.gov in the United States, the WHO International Clinical Trials Registry Platform, and the EU Clinical Trials Register. This is the single most useful entry in this chapter's reading list. Search a compound name and you learn, in under a minute, whether anyone has committed to studying it in humans, in what population, on what endpoint. A null result here is informative in a way that a null result in a literature search is not, because registration is the mechanism that catches unpublished negative trials.

PubMed. Search thymosin beta-4 and search TB-500 separately. Do not merge the searches. Note what each returns, note the species and the molecule in each abstract, and note the difference in volume. That exercise takes fifteen minutes and teaches Case Study 18.2 more effectively than reading it does.

Regulatory agency databases. The FDA's approved-drug databases, the EMA's medicine listings, and equivalent national registers. These answer the "is it approved, where, and for what?" question directly, and they answer it with the indication attached — which, per §18.3, is the part that usually gets dropped.

A current cell biology textbook, on actin dynamics. Any standard text. The material on G-actin, F-actin, polymerization, and cell motility is settled, well-taught, and the honest foundation for understanding what thymosin β4 does biochemically. Reading it will also make clear how far "participates in regulating actin polymerization" is from "heals your rotator cuff."

A current immunology textbook, on innate and adaptive immunity. Read the chapter listing the cell populations and the major cytokines. Then reread §18.6. The reason "immune modulation" is unfalsifiable becomes visceral once you have seen how many independently regulated components the phrase is being asked to cover.

Reporting-standards documents for preclinical research. Guidelines exist for the design and reporting of animal experiments — randomization, blinding, sample size justification, and complete reporting of animals used. Reading one will tell you what a well-conducted animal study looks like and therefore what to check for. It will also show you, by contrast, how much published animal work predates or ignores them.

Tier 2 — Attributed, specifics unverified

Bodies of literature this chapter refers to as existing, described in general terms rather than by citation. Everything here is real as a body of work. Individual claims about any specific paper — its authors, its journal, its year, its exact findings — are not verified in this text, and this book will not manufacture them.

The thymosin β4 preclinical repair literature. Dermal wound healing, cardiac repair after injury, and corneal healing are the three areas where the work is concentrated. It is genuine academic research published in peer-reviewed journals over a sustained period. To engage with it, search the molecule's proper name and read abstracts directly rather than relying on summaries — the summaries are where the parent/fragment conflation enters.

Human clinical investigation of thymosin β4. Investigation has occurred, with corneal and dermal indications the areas that appear to have gone furthest. It has not produced an approved product for tissue repair in a major jurisdiction. Registries and regulatory databases are the way to check the current state of this rather than any secondary summary, including this one.

The thymosin alpha-1 clinical literature. Randomized human trials exist in chronic hepatitis B, in sepsis, and in immune support during cancer treatment. The literature is heterogeneous in design, population, endpoint, and quality, and reported effect sizes are contested. If you read only one thing from this tier, look for a systematic review or meta-analysis of Tα1 in a single indication and pay attention to the review's own account of study quality — that account, more than the pooled estimate, is what tells you where the evidence sits.

The LL-37 and cathelicidin literature. Substantial and active, covering direct antimicrobial activity, immunomodulatory functions, and the selectivity problem inherent to membrane-disrupting mechanisms. Chapter 25 handles it properly; this chapter deliberately does not.

The KPV and α-MSH anti-inflammatory literature. Preclinical, concentrated in models of intestinal inflammation. Worth reading as an example of a fragment studied under its own name rather than inheriting a parent's citations — the contrast with §18.1 is instructive.

The larazotide clinical program in celiac disease. Human trials have been conducted. Reading the registry entries alongside any published results is a useful exercise in comparing what was planned with what was reported — a skill Chapter 7 develops.

Angiogenesis and tumor biology. The requirement of a blood supply for tumor growth beyond a minimal size, and the role of evading programmed cell death, are foundational and extensively documented. Any current review of the hallmarks of cancer covers both. §18.7's symmetric concern follows directly and requires no exotic source.

Veterinary and equine use of compounds in this class. Real, documented, and covered in Chapter 31. Read that chapter before drawing conclusions in either direction — a use is not a credential, and "it's used in racehorses" is a question about regulatory arbitrage and testing regimes at least as much as a statement about pharmacology.

Tier 3 — Illustrative and constructed

Material created for teaching. Not evidence, and not to be cited as such.

Figure 18.1, "What a repair-model animal study can and cannot tell you." A constructed composite representing the standard design used across the thymosin β4 repair literature. It is labeled as such in the chapter. No number or result in it is drawn from any real paper — it exists to teach the shape of the design and the shape of what such a design cannot show.

The claim quotations in the ⚠️ Hype Check callouts. Paraphrased composites of claim types, not quotations from any identified source, person, or company. They are written to be representative rather than to be attributable, and no vendor, clinic, or individual is named anywhere in this chapter — deliberately, because the naming convention and the marketing language are industry-wide and inherited rather than the work of a bad actor you could point at.

The Dossier worked demonstrations. Field 5 entries for TB-500 and thymosin alpha-1 are written as teaching models. They demonstrate the format and the reasoning. Verify every factual line yourself before relying on it, using the Tier 1 sources above — and note that doing so is the exercise, not a chore attached to it.

The three-row regulatory diagram in §18.3 and the "four things an immune claim must specify" box in §18.6. Analytical frameworks constructed for this book. They are arguments, not findings. Test them against cases; if you find a case that breaks one, the framework is wrong and the case is right.

If you only do one thing

Open a trial registry and search both names — "thymosin beta-4" and "TB-500" — as separate queries. Then do the same on PubMed.

Four searches. Ten minutes.

You will see, without anyone interpreting it for you, exactly what §18.1 and Case Study 18.2 describe: one name returns a body of research, the other returns something very different, and the parenthesis that joins them in every product description is doing work no one has earned. Then run the same four searches on any compound you are actually considering.

That habit — check the registry, check the molecule name, check the species — is more valuable than anything else in this chapter, and it will still work in ten years when every specific fact here has been superseded.